Kirsten Bibbins-Domingo, the Editor in Chief of JAMA, dives into groundbreaking trials from the ESC 2024 Congress. She discusses the impact of antihypertensive continuation before surgery and potassium's role post-cardiac surgery. A key highlight is a triple-drug combination pill aimed at tackling resistant hypertension in Africa, showing promise in improving patient outcomes. Lastly, Bibbins-Domingo emphasizes innovative methods to manage hypertension in Nigeria, pointing to a significant leap in treatment efficacy. This conversation is a treasure trove for cardiovascular health enthusiasts.
Continuing antihypertensive medications until surgery day does not significantly increase post-operative complications but may lead to intraoperative hypotension.
A low-dose triple-drug combination pill significantly improves hypertension management in Nigeria, showcasing a need for better treatment strategies in sub-Saharan Africa.
Deep dives
Antihypertensive Medications and Elective Surgery
Research indicates that patients with hypertension undergoing elective major non-cardiac surgery may reasonably continue their antihypertensive medications until the day of the procedure. A multi-center trial compared the outcomes of patients who continued their ACE inhibitors or angiotensin receptor blockers to those who stopped them 48 hours prior. The trial found no significant difference in post-operative complications or all-cause mortality between the two groups, although those continuing medications experienced more prolonged intraoperative hypotension. These findings suggest the importance of monitoring patients for hypotension while considering the safe continuation of essential medications during surgery.
Innovation in Hypertension Management in Sub-Saharan Africa
A study evaluating a novel low-dose triple combination pill for hypertension treatment in Nigeria demonstrated significant effectiveness compared to standard care. Participants taking the combination pill, which included telmisartan, amlodipine, and indapamide, achieved better blood pressure control and a higher percentage met the target goals as measured in home settings. Although the triple pill group experienced slightly more adverse effects like mild hypokalemia, the overall low discontinuation rates suggest good tolerability. This trial highlights the need for effective strategies to manage hypertension in sub-Saharan Africa, where control rates remain critically low.
1.
Highlights from Major Clinical Trials in Cardiovascular Health
JAMA Editor in Chief Kirsten Bibbins-Domingo reviews 4 JAMA trials presented at this year’s European Society of Cardiology (ESC) Congress on antihypertensive continuation before elective surgery, potassium supplementation after cardiac surgery, pulmonary vein isolation for symptomatic atrial fibrillation, and a triple-drug combination pill for resistant hypertension in Africa.
Correction: an earlier version of this podcast contained an error in the conclusion of the TIGHT K trial summary, which has been updated. Related Content: